Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.32), $0.08 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $57 million versus the consensus estimate of $52.06 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.